Genprex, Inc. (GNPX)Â
NASDAQ$0.342
Market Cap
$2.91M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
604 of 919
Rank in Industry
346 of 523
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
GNPX Insider Trading Activity
GNPX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Insider Activity of Genprex, Inc.
Over the last 12 months, insiders at Genprex, Inc. have bought $0 and sold $0 worth of Genprex, Inc. stock.
On average, over the past 5 years, insiders at Genprex, Inc. have bought $51,887 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $21,478 was made by VACZY CATHERINE M (EVP GC Chief Strategy Officer) on 2023‑04‑21.
List of Insider Buy and Sell Transactions, Genprex, Inc.
| 2023-04-21 | VACZY CATHERINE M | EVP GC Chief Strategy Officer | 20,000 0.0426% | $1.07 | $21,478 | -70.00% | ||
| 2023-04-21 | Varner John Rodney | Chairman, President and CEO | 19,000 0.0398% | $1.05 | $20,045 | -70.00% | ||
| 2021-04-05 | LONGNECKER BRENT M | director | 15,000 0.0313% | $4.15 | $62,250 | -37.14% | ||
| 2019-09-05 | Varner John Rodney | Chief Executive Officer | 1,800 0.0116% | $0.89 | $1,595 | +158.62% | ||
| 2018-07-30 | Pham Julien L | President & COO | 500 0.0038% | $3.40 | $1,700 | -47.75% | ||
| 2018-03-29 | ROTH JACK A | 10 percent owner | 40,000 0.3625% | $5.00 | $200,000 | -53.19% | ||
| 2018-03-29 | Varner John Rodney | Chief Executive Officer | 10,000 0.0906% | $5.00 | $50,000 | -53.19% | ||
| 2018-03-29 | Nance Christy M. | 10 percent owner | 50,000 0.4531% | $5.00 | $250,000 | -53.19% |
Total: 8
Insider Historical Profitability
<0.0001%
| ROTH JACK A | 10 percent owner | 1338999 15.738% | $457,937.66 | 1 | 0 | <0.0001% |
| VACZY CATHERINE M | EVP GC Chief Strategy Officer | 265000 3.1147% | $90,630.00 | 1 | 0 | <0.0001% |
| Nance Christy M. | 10 percent owner | 50000 0.5877% | $17,100.00 | 1 | 0 | <0.0001% |
| Varner John Rodney | Chairman, President and CEO | 20800 0.2445% | $7,113.60 | 3 | 0 | <0.0001% |
| LONGNECKER BRENT M | director | 15000 0.1763% | $5,130.00 | 1 | 0 | <0.0001% |
| Pham Julien L | President & COO | 500 0.0059% | $171.00 | 1 | 0 |
Historical Insider Profitability vs. Competitors
$1,138,733 | 28 | -4.94% | $2.87M | |
$63,749,694 | 24 | -12.24% | $2.43M | |
$193,112 | 22 | -20.59% | $1.61M | |
$1,616,354 | 20 | -12.22% | $3.36M | |
$613,181 | 18 | -20.90% | $2.06M | |
$960,082 | 17 | -6.29% | $2.94M | |
$111,212 | 12 | -28.79% | $3.17M | |
$4,146,041 | 11 | -40.86% | $1.04M | |
$111,748 | 9 | -47.72% | $3.27M | |
$100,375 | 8 | -51.85% | $3.19M | |
$159,974 | 7 | -18.60% | $3.37M | |
$53,399 | 6 | -70.96% | $3.03M | |
Genprex, Inc. (GNPX) | $603,773 | 6 | -56.12% | $2.91M |
$3,509,515 | 3 | -43.81% | $1.66M | |
$37,465 | 3 | -40.67% | $2.78M | |
$12,240 | 2 | -1.26% | $1.81M | |
$2,140 | 1 | -59.50% | $3.08M | |
$100,542 | 1 | -64.44% | $1.12M | |
$739,010 | 1 | 3.33% | $3.54M |
GNPX Institutional Investors: Active Positions
| Increased Positions | 10 | +47.62% | 137,495 | +62.93% |
| Decreased Positions | 6 | -28.57% | 64,731 | -29.63% |
| New Positions | 4 | New | 31,906 | New |
| Sold Out Positions | 2 | Sold Out | 527 | Sold Out |
| Total Postitions | 25 | +19.05% | 291,236 | +33.31% |
GNPX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Virtu Financial Llc | $29.00 | 0.89% | 80,424 | +31,400 | +64.05% | 2024-12-31 |
| Geode Capital Management, Llc | $27.00 | 0.85% | 76,045 | +59,798 | +368.06% | 2024-12-31 |
| Goldman Sachs Group Inc | $9.00 | 0.29% | 26,431 | +26,431 | New | 2024-12-31 |
| Two Sigma Securities, Llc | $7.00 | 0.21% | 18,990 | -4,050 | -17.58% | 2024-12-31 |
| Hrt Financial Lp | $6.00 | 0.19% | 17,076 | +1,536 | +9.88% | 2024-12-31 |
| Vanguard Group Inc | $5.00 | 0.17% | 15,315 | 0 | 0% | 2024-12-31 |
| Hightower Advisors, Llc | $5.00 | 0.15% | 13,827 | -7,200 | -34.24% | 2024-12-31 |
| Blackrock, Inc. | $3.00 | 0.11% | 9,485 | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $3.00 | 0.1% | 9,373 | +7,799 | +495.49% | 2024-12-31 |
| Ubs Group Ag | $2.00 | 0.07% | 6,686 | -49,673 | -88.14% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.